A new method uses the auxin-inducible degron (AID) system to tune protein levels with precision in living C. elegans.

Pairing a drug that targets the PRDM9 gene with a cholesterol-lowering agent shrank brain tumors and improved survival in mice.

Results open the door to therapies based on chronobiology, the branch of biology that studies how living organisms structure their physiological processes in time.

As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...